QUIZ

Eligibility Pre-Screening

Do you have a medical condition that has lasted more than 3 months?
Have conventional medicines/treatments failed to fully resolve your medical condition or have you avoided treatments due to negative side effects?
Submit
This self-assessment is for informational purposes and is not a qualified medical opinion. In case of health emergency, call your local emergency number immediately. By submitting this quiz, you are confirming that you have read and agree to our Terms & Conditions and Privacy Statement.

Is medicinal cannabis for you?

Fast, simple & legal
access in Australia.
Free Eligibility Test

Power Play – Impression Healthcare Announces Appointment of Dr Sud Agarwal

Impression Healthcare has made key leadership and board changes.

 

Impression Healthcare (ASX:IHL) has appointed an internationally recognised key opinion leader in cannabinoid medicines, Dr Sud Agarwal, as the company’s Chief Medical Officer and Non-Executive Director.

 

The appointment will add significant medical, scientific and cannabis-related expertise to the company’s senior management team, and will aid in Impression Healthcare’s current and future research, as well as its ongoing commercial programs.

 

The company has also formed a Medical Advisory Board which is to be headed by Dr Agarwal—who is a qualified anaesthetist, the former Medical Director of the Cann Group and current CEO and Managing Director of Cannvalate—which will oversee clinical trial programs, product commercialisation strategies and assist with furthering defendable intellectual property.

 

The CEO and Managing Director of Impression Healthcare, Joel Latham, said that the company is “delighted that Dr Agarwal has joined our team as an expert and early-mover in the medicinal cannabis field.”

 

“His appointment is game-changing to the rapid commercialisation of key proprietary drugs being developed by IHL. His experience and knowledge are second-to-none and will help to perfect our strategy in the cannabis field whilst also opening the Company to global opportunities in this rapidly advancing sector”.

– Managing Director and CEO of Impression Healthcare, Joel Latham

 

As part of his role on the company’s Medical Advisory Board, Agarwal will bring his extensive cannabis expertise to Impression’s current and upcoming clinical programs, targeting conditions such as sleep apnoea, concussion, gum disease and TMJ disorder.

 

According to senior management, Agarwal’s ability to leverage patient groups will also support the company’s strategy for brining Impression’s products to the commercial market.

 

Please read the full article here.

Leave Comments

Your email address will not be published. Required fields are marked *